Floatz logo

Bortezomib

Waldenstrom Macroglobulinemia

Seoul National University HospitalSmall moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Waldenstrom Macroglobulinemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Inno-206
BeOne Medicines
Phase 2BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →